A Study of Anti-PD-L1 Antibody in Perioperative Chemotherapy of Esophageal Carcinoma.
Last updated on July 2021Recruitment
- Recruitment Status
- Not yet recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Esophageal Cancer
- Type
- Interventional
- Phase
- Phase 1Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 70 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04460066
- Collaborators
- Not Provided
- Investigators
- Study Director: SHUGENG GAO, MD Chinese Academy of Medical Sciences and Peking Union Medical College
Get Well Soon